The University of Southampton
University of Southampton Institutional Repository

Escitalopram in the treatment of generalized anxiety disorder

Escitalopram in the treatment of generalized anxiety disorder
Escitalopram in the treatment of generalized anxiety disorder
The selective serotonin reuptake inhibitor escitalopram is the active enantiomer of citalopram and has proven efficacy in the treatment of major depression, panic disorder and social phobia. Accumulating data indicate that it is also efficacious in the treatment of patients with generalized anxiety disorder. This drug profile summarizes the current evidence-base for the treatment of generalized anxiety disorder, describes the findings of a series of randomized placebo-controlled and comparator-controlled trials of escitalopram, examines the strengths and weaknesses of current treatment approaches and considers potential new therapies for the treatment of this common, chronic and impairing anxiety disorder. In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.
efficacy, escitalopram, generalized anxiety disorder, pharmacotherapy, placebo, safety
1473-7175
443-449
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Nair, Rajesh V.
23d1b46a-396c-4149-93d5-f4165549b19d
Baldwin, David S.
1beaa192-0ef1-4914-897a-3a49fc2ed15e
Nair, Rajesh V.
23d1b46a-396c-4149-93d5-f4165549b19d

Baldwin, David S. and Nair, Rajesh V. (2005) Escitalopram in the treatment of generalized anxiety disorder. Expert Review of Neurotherapeutics, 5 (4), 443-449. (doi:10.1586/14737175.5.4.443).

Record type: Article

Abstract

The selective serotonin reuptake inhibitor escitalopram is the active enantiomer of citalopram and has proven efficacy in the treatment of major depression, panic disorder and social phobia. Accumulating data indicate that it is also efficacious in the treatment of patients with generalized anxiety disorder. This drug profile summarizes the current evidence-base for the treatment of generalized anxiety disorder, describes the findings of a series of randomized placebo-controlled and comparator-controlled trials of escitalopram, examines the strengths and weaknesses of current treatment approaches and considers potential new therapies for the treatment of this common, chronic and impairing anxiety disorder. In summary, escitalopram is effective and well tolerated in both the short- and long-term treatment of generalized anxiety disorder, and has advantages over benzodiazepines and the selective serotonin reuptake inhibitor paroxetine.

Full text not available from this repository.

More information

Published date: 2005
Keywords: efficacy, escitalopram, generalized anxiety disorder, pharmacotherapy, placebo, safety

Identifiers

Local EPrints ID: 27527
URI: http://eprints.soton.ac.uk/id/eprint/27527
ISSN: 1473-7175
PURE UUID: fd418906-a48d-495d-98cb-8095cd84a0ec

Catalogue record

Date deposited: 25 Apr 2006
Last modified: 15 Jul 2019 19:12

Export record

Altmetrics

Contributors

Author: Rajesh V. Nair

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×